Dexamethason 8 mg JENAPHARM®
Sponsors
Glaxosmithkline Research & Development Limited, Sanofi-Aventis Recherche & Developpement, Celgene Corp.
Conditions
CancerCancer - Plasma cell myeloma recurrentMultiple MyelomaMultiple myelomaPlasma cell myelomaRelapsed and refractory multiple myeloma (RRMM)Relapsed/Refractory Multiple Myeloma
Phase 1
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)–DREAMM5.
Active, not recruitingCTIS2023-509550-55-00
Start: 2020-01-21Target: 62Updated: 2025-10-10
Phase 1/2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma (RRMM) - Master protocol
Phase 1/2 trial evaluating isatuximab with or without dexamethasone in combination with novel agents compared to isatuximab with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM) - control arm
RecruitingCTIS2024-514988-25-00
Start: 2021-03-31Target: 7Updated: 2026-01-23
Phase 1/2 trial evaluating isatuximab in combination with belantamab mafodotin and dexamethasone in relapsed or refractory multiple myeloma (RRMM)
Active, not recruitingCTIS2024-514989-40-00
Start: 2021-05-17Target: 3Updated: 2026-01-22
Phase 1/2 trial evaluating isatuximab in combination with evorpacept and dexamethasone in relapsed or refractory multiple myeloma (RRMM)
RecruitingCTIS2024-514993-38-00
Start: 2021-03-31Target: 19Updated: 2026-01-23
Phase 1/2 trial evaluating isatuximab in combination with SAR445761 (belumosudil) and dexamethasone in relapsed or refractory multiple myeloma (RRMM)
RecruitingCTIS2024-514992-16-00
Start: 2021-03-31Target: 17Updated: 2026-01-23
Phase 2
A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma
CompletedCTIS2023-508727-12-00
Start: 2018-04-12End: 2025-09-02Target: 46Updated: 2025-10-15
International, multi-center, open-label, treatment extension study in patients with multiple myeloma who are still benefitting from isatuximab-based therapy following completion of a Phase 1, 2, or 3 parental study
Active, not recruitingCTIS2023-507180-19-00
Start: 2023-04-05Target: 37Updated: 2025-12-01
Phase 3
A Phase 3 randomized, open-label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma
Active, not recruitingCTIS2023-507419-37-00
Start: 2020-06-25Target: 272Updated: 2025-10-06
A randomized, Phase 3, open label study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma (RRMM)
Active, not recruitingCTIS2023-508869-32-00
Start: 2022-11-10Target: 217Updated: 2025-10-09
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma
Active, not recruitingCTIS2023-510537-28-00
Start: 2020-05-15Target: 203Updated: 2025-10-30
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Active, not recruitingCTIS2023-506877-37-00
Start: 2020-09-28Target: 148Updated: 2025-12-15
A Phase 3, randomized, open-label study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone versus daratumumab, lenalidomide, and dexamethasone in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (TI-NDMM)-DREAMM-10
RecruitingCTIS2024-516030-35-00
Start: 2025-04-30Target: 225Updated: 2025-10-16